Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)

Go Back to All Clinical Trials

Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)

Brief description of study

This is a Phase I, open-label, multicentre trial of BI 1810631 administered orally as a single agent. The trial has two parts; Phase Ia, which is the dose escalation part (non-randomised), and Phase Ib which is the dose expansion part. The dose expansion part will consist of 3 cohorts. If needed, the expansion part will include a randomised dose optimization in Cohort 1

Clinical Study Identifier: s22-01411

ClinicalTrials.gov Identifier: NCT04886804

Principal Investigator: Joshua K Sabari.

Other Investigators: Samantha VanMaanen, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Sally Lau, David Mendoza, Natalia Cherkassky, Vamsidhar Velcheti, Melissa L Martinez, Kirby Rodriguez.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies